Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology
Novo Nordisk's investigational drug CagriSema showed ~21% average weight loss in the REDEFINE 9 trial, with 19.4% and 18.6% weight loss at lower doses compared to 4.6% with placebo. The trial was presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology. Novo filed a New Drug Application with the FDA in December 2025, with a decision expected in Q4 2026.
How this was made
The 30-second read
Why it matters
The trial data could move Novo's stock as investors reassess the drug's market potential ahead of the Q4 2026 FDA decision.
Market read
First disclosure of pivotal trial results; material for Novo's valuation and obesity drug sector.
What to watch
Potential competition from other GLP‑1 combos and payer reimbursement challenges.
Background
Novo Nordisk is a leading diabetes and obesity drugmaker; CagriSema combines cagrilintide and semaglutide.
Ticker impact
Novo Nordisk reported phase 3 trial data showing ~21% average weight loss for CagriSema, a new GLP‑1/amylin combo.
likely upward pressure as market prices in potential approval and market opportunity.
Phase 3 data with statistically significant weight loss and favorable safety profile are material for a listed biotech.
Market effects
May accelerate interest in obesity therapeutics and GLP‑1 combo pipelines.
European biotech sector could see heightened attention.
Obesity drug market globally could be reshaped if Novo secures approval.
Counterpoint
Skeptics may question long‑term safety and commercial pricing before FDA approval.
Key entities
- companyNovo Nordisk A/S
Global healthcare company developing CagriSema.
- productCagriSema
Investigational GLP‑1 and amylin analog for obesity.
